301. In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma.
- Author
-
Hau DK, Zhu GY, Leung AK, Wong RS, Cheng GY, Lai PB, Tong SW, Lau FY, Chan KW, Wong WY, Lam KH, Cheng CH, Cheung F, Chui CH, Gambari R, and Fong DW
- Subjects
- Animals, Antineoplastic Agents, Phytogenic administration & dosage, Antineoplastic Agents, Phytogenic pharmacology, Cell Line, Tumor, Glucosides administration & dosage, Glucosides pharmacology, Humans, Hydrolyzable Tannins, Liver drug effects, Liver enzymology, Mice, Mice, Nude, Plant Extracts administration & dosage, Plant Extracts pharmacology, Xenograft Model Antitumor Assays, Antineoplastic Agents, Phytogenic therapeutic use, Carcinoma, Hepatocellular drug therapy, Glucosides therapeutic use, Liver Neoplasms drug therapy, Phytotherapy, Plant Extracts therapeutic use
- Abstract
We have investigated the potential in vivo anti-tumour activity of corilagin using the Hep3B hepatocellular carcinoma cell line and an athymic nude mice xenograft model. The purity of corilagin was confirmed by high performance liquid chromatographic analysis. Corilagin was administrated intraperitoneally for a continuous period of 7 days at a concentration of 15 mg/kg of body weight per day. A significant inhibition of tumour growth was observed when treated mice are compared with control groups. Furthermore, analysis of enzymes markers of liver function, including alanine aminotransferase and asparate aminotransferase, suggested that current therapeutic dosage of corilagin did not exert adverse effect on liver. Our observations support the view that corilagin is considerably effective to retard the in vivo growth of xenografted Hep3B hepatocellular carcinoma., (Copyright © 2010 Elsevier GmbH. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF